+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Tiotropium: a new, long-acting agent for the management of COPD--a clinical review



Tiotropium: a new, long-acting agent for the management of COPD--a clinical review



Director 12(3): 160 162-4



Tiotropium is a major advance in the management of COPD. Clinical trials have shown that this product administered once a day improves overall lung function, reduces dyspnea, improves quality of life, and reduces hospitalizations. It does have the common adverse effect of an increase in dry mouth. The once-a-day dosing and easy-to-use HandiHaler device should improve patient compliance. Overall, based on the product profile, tiotropium appears to be an effective first-line agent in the management of COPD in the nursing home.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 050795635

Download citation: RISBibTeXText

PMID: 15323298


Related references

Tiotropium, a long-acting bronchodilating agent for the treatment of COPD. Nederlands Tijdschrift Voor Geneeskunde 150(22): 1227-1232, 2006

The role of tiotropium bromide, a long-acting anticholinergic bronchodilator, in the management of COPD. Treatments in Respiratory Medicine 4(4): 275-281, 2005

Comparison of indacaterol with tiotropium or twice-daily long-acting β -agonists for stable COPD: a systematic review. Chest 142(5): 1104-1110, 2012

Pharmacological and clinical profile of tiotropium bromide (Spiriva), a new long-acting anticholinergic bronchodilator for COPD treatment. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 125(5): 307-313, 2005

Short Term Effects of Tiotropium on COPD Patients Treated with Long Acting Bronchodilators. Tanaffos 11(1): 26-31, 2012

Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids. Respirology 11(5): 598-602, 2006

Tiotropium is less likely to induce oxygen desaturation in stable COPD patients compared to long-acting beta2-agonists. Respiratory Medicine 101(8): 1798-1803, 2007

Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?. Current Opinion in Pharmacology 3(3): 270-276, 2003

Tiotropium (Spiriva) - a long-acting inhaled anticholinergic for the treatment of chronic obstructive pulmonary disease (COPD). Pneumologie 57(9): 519-525, 2003

The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest 141(1): 81-86, 2012

Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest 146(6): 1521-1530, 2014

Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD - real-life experience from an observational study. International Journal of Chronic Obstructive Pulmonary Disease 10: 613-623, 2015

One-year mortality associated with COPD treatment: a comparison of tiotropium and long-acting beta2-agonists in three Italian regions: results from the OUTPUL study. Pharmacoepidemiology and Drug Safety 25(5): 578-589, 2016

Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2015(10): Cd008989, 2015